- Thinly traded nano cap Vivus (VVUS +21.3%) is up on almost a 6x surge in volume, the latest member of spiking tiny biotechs.
- The stock is currently exchanging hands at $2.98, well below its quick asset value per share based on Q3 numbers. At the end of September, cash and equivalents and available-for-sale securities totaled $115.1M or $10.83 per share. Operations consumed $26.7M during the first three quarters so, assuming similar cash consumption in Q4, the cash value per share will be ~$10 at year-end.
- The company is planning to relaunch PANCREAZE next quarter. It also plans to obtain additional regulatory approvals and partners in open territories for STENDRA/SPEDRA and certain territories for QSYMIA (corporate presentation, slide #19).